BioCryst Pharma Posts Narrower Loss In Q4; Raises FY25 ORLADEYO Revenue Guidance

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) posted a net loss for the fourth quarter of $26.8 million, or $0.13 per share, compared to a net loss of $61.7 million, or $0.31 per share, for the fourth quarter of 2023. Analysts on average expected the company to report a loss per share of $0.06, for the quarter. Analysts' estimates typically exclude special items.

Total revenues were $131.5 million, compared to $93.4 million in the fourth quarter of 2023. The company said the increase was primarily due to $124.2 million in ORLADEYO net revenue in the fourth quarter of 2024, compared to $90.9 million in the fourth quarter of 2023. Analysts on average had estimated $130.05 million in revenue.

The company has increased full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million, from prior guidance of $515 million to $535 million. The company now expects full year 2025 total revenue will be between $560 million and $575 million, revised from prior guidance of $540 million to $560 million.

The company expects to approach quarterly positive EPS and positive cash flow in the second half of 2025, and to be profitable on an EPS basis, with positive cash flow, for full year 2026. Over the next three years, the company expects an annual CAGR for revenue of around 20 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.